v3.26.1
Net Loss Per Share
3 Months Ended
Mar. 31, 2026
Net Loss Per Share  
Net Loss Per Share

18. Net Loss Per Share

The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of shares of Common Stock outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per share of Common Stock after giving consideration to all potentially dilutive shares of common stock, including options to purchase common stock and warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential shares of Common Stock have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.

The following table sets forth the computation of basic and diluted net loss per share for the three months ended March 31, 2026 and 2025:

 

 

Three Months Ended March 31,

 

 

2026

 

 

2025

 

Numerator:

 

 

 

 

 

 

Loss from continuing operations

 

$

(26,706

)

 

$

(8,461

)

Income from discontinued operations

 

 

19,585

 

 

 

 

Less: Net (loss) income attributable to noncontrolling interests

 

 

(243

)

 

 

(15

)

Net loss attributable to ASP Isotopes Inc. shareholders

 

 

(6,878

)

 

 

(8,446

)

Denominator:

 

 

 

 

 

 

Weighted average common stock outstanding, basic and diluted

 

 

121,000,699

 

 

 

69,484,200

 

Net (loss) income per share, basic and diluted:

 

 

 

 

 

 

Continuing operations

 

 

(0.22

)

 

 

(0.12

)

Discontinued operations

 

 

0.16

 

 

 

-

 

Attributable to ASP Isotopes Inc. shareholders

 

 

(0.06

)

 

 

(0.12

)

The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:

 

 

As of March 31,

 

 

2026

 

 

2025

 

Options to purchase common stock

 

 

794,835

 

 

 

2,610,166

 

Restricted stock

 

 

3,629,800

 

 

 

2,357,588

 

Warrants to purchase common stock

 

 

69,778

 

 

 

1,516,297

 

Total shares of common stock equivalents

 

 

4,494,413

 

 

 

6,484,051